Abnormalities in serum parathyroid hormone (PTH) are exceedingly common in end-stage renal disease (ESRD) patients on maintenance dialysis and associated with cardiovascular disease, disturbances in bone mineral disorders, even increased morbidity and mortality in most epidemiologic studies [1, 2]. The gene discussed is PTH; the disease is cardiovascular disorder.